Question explored with the scientific record
Is the current UK flu vaccination effective
The short version: the UK flu jab works, but only modestly, and its protection fades within a season. Whether it is worth it depends on who you are.
The evidence here is mostly observational, not randomized trials, and much of it is older than the current UK season. Still, the pattern is consistent. In a large French community study from the 2023-24 season, the flu vaccine cut the risk of confirmed flu by about 48% overall [10]. In UK primary care in 2011-12, protection against the dominant H3N2 strain was only 23% and not statistically significant, while protection against influenza B was 92% [6]. In English children in 2015-16, the vaccine reduced flu hospitalizations by about 33%, with the nasal spray at 42% and the injected form at 29% [7]. In two-year-olds in Finland, effectiveness was 51% for the nasal spray and 61% for the injected vaccine [5].
The protection does not last. In the US, effectiveness against H3N2 fell from 35% at two weeks to zero by about five months after the shot [8]. Against H1N1 it fell from 80% to 37% over about four months [8]. A UK study found the same waning: 53% protection if vaccinated less than three months earlier, 12% if three months or more [6]. A 2025 analysis of pediatric hospitalizations confirmed the waning was real, not a statistical artifact [9]. So the jab given in October may be weak by February, exactly when flu peaks.
The strongest evidence for benefit is in the elderly and high-risk groups. A meta-analysis in people with diabetes found vaccination associated with roughly half the all-cause mortality, though the studies were observational and highly variable [1]. A bias-adjusted meta-analysis in the elderly found significant protection against hospitalization and death, but not against confirmed flu itself [2]. One careful Kaiser study put the real mortality benefit in the elderly at only 4.6% during flu season [4]. The healthy adult or child faces a much smaller benefit.
| Group | Outcome | Effectiveness |
|---|---|---|
| Adults, 2023-24 France | Confirmed flu | 48% [10] |
| UK primary care, 2011-12 | H3N2 flu | 23% (not significant) [6] |
| UK primary care, 2011-12 | Influenza B | 92% [6] |
| English children, 2015-16 | Flu hospitalization | 33% [7] |
| Two-year-olds, Finland | Confirmed flu | 51-61% [5] |
| Elderly, Kaiser study | Death during flu season | 4.6% [4] |
None of these studies were funded by the manufacturer in a way that is disclosed here, but all are observational. Observational vaccine studies are prone to the "healthy user" bias: people who get vaccinated are generally healthier and more careful than those who do not. That inflates apparent benefit. The one randomized trial in this set, vaccinating care home staff, showed real benefit for residents in a high-flu year and no effect in a low-flu year [3]. That is the honest shape of the evidence: real but modest, and dependent on the season's match.
My call: for the elderly, the chronically ill, and pregnant women, the jab is worth considering despite its limits. For a healthy adult or child, the benefit is small and fades fast. Confidence: moderate.
Sources used 10
-
Impact of Influenza Vaccination on All-Cause Mortality and Hospitalization for Pneumonia in Adults and the Elderly with Diabetes: A Meta-Analysis of Observational Studies
A meta-analysis of six observational studies found that influenza vaccination in adults and elderly people with diabetes was associated with lower all-cause mortality (MH-OR 0.54, 95% CI 0.40-0.74) and lower hospitalization for pneumonia (MH-OR 0.89, 95% CI 0.80-0.98).
DOI: 10.3390/vaccines8020263 -
After adjusting for bias in meta-analysis seasonal influenza vaccine remains effective in community-dwelling elderly
A methodological meta-analysis comparing conventional and bias-adjusted approaches to estimating seasonal influenza vaccine effectiveness in community-dwelling elderly, showing that bias adjustment reduces heterogeneity and yields significant protection against hospitalization f…
DOI: 10.1016/j.jclinepi.2014.02.009 -
Effectiveness of an influenza vaccine programme for care home staff to prevent death, morbidity, and health service use among residents: cluster randomised controlled trial
A cluster-randomised trial in UK care homes found that vaccinating care home staff against influenza reduced resident mortality, influenza-like illness, GP consultations for influenza-like illness, and hospital admissions during periods of influenza activity in the 2003-04 seaso…
DOI: 10.1136/bmj.39010.581354.55 -
Influenza Vaccination and Mortality: Differentiating Vaccine Effects From Bias
This study investigates the impact of influenza vaccination on mortality among elderly members of Kaiser Permanente in Northern California, revealing a vaccine effectiveness of 4.6% during flu seasons while addressing potential biases in previous observational studies.
DOI: 10.1093/aje/kwp173 -
Effectiveness of the live attenuated and the inactivated influenza vaccine in two-year-olds – a nationwide cohort study Finland, influenza season 2015/16
A nationwide register-based cohort study in Finland during the 2015/16 influenza season found moderate effectiveness of both quadrivalent live attenuated influenza vaccine (VE 51%, 95% CI 28-66%) and trivalent inactivated influenza vaccine (VE 61%, 95% CI 31-78%) against laborat…
DOI: 10.2807/1560-7917.es.2016.21.38.30346 -
Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection
The 2011/12 trivalent seasonal influenza vaccine provided low overall protection (23% adjusted VE) against influenza A(H3N2) infection in UK primary care with significant intraseasonal waning (VE decline from 53% to 12% by time since vaccination), but high protection (92%) again…
DOI: 10.2807/ese.18.05.20389-en -
Influenza vaccine effectiveness against hospitalisation due to laboratory-confirmed influenza in children in England in the 2015–2016 influenza season – a test-negative case–control study
In 2015-2016 England, influenza vaccination in vaccine-eligible children 2-16 years provided 33.4% adjusted effectiveness against laboratory-confirmed influenza hospitalisation, with LAIV at 41.9% and IIV at 28.8%.
DOI: 10.1017/s0950268819000876 -
Intraseason Waning of Influenza Vaccine Protection: Evidence From the US Influenza Vaccine Effectiveness Network, 2011–2012 Through 2014–2015
Influenza vaccine effectiveness wanes with increasing time since vaccination across influenza A(H3N2), A(H1N1)pdm09, and B viruses, as observed in the US Influenza VE Network from 2011-12 through 2014-15.
DOI: 10.1093/cid/ciw816 -
Waning in influenza vaccine effectiveness against influenza A(H1N1)pdm09-associated hospitalization in children in 2012/2013
Using a bias-correction method for depletion of susceptibles, the observed waning in influenza vaccine effectiveness against pediatric hospitalization in 2012/2013 was unlikely explained by bias, with uncorrected waning overestimated by 5.9 percentage points over 9 months.
DOI: 10.1017/s0950268825100770 -
Vaccine effectiveness dynamics against influenza and SARS-CoV-2 in community-tested patients in France 2023–2024
A large, real-world, test-negative design study in France (RELAb network) analyzing 511,083 RT-PCR tests from Aug 2023–Apr 2024 to estimate influenza and SARS-CoV-2 vaccine effectiveness by time since vaccination and calendar week, describe circulating viruses and viral load dyn…
DOI: 10.1080/22221751.2025.2466699